283 Results

People

  1. Pasternak
    Pasternak
  2. Young
    Young
  3. Niedzwiecki
    Niedzwiecki
  4. Humm
    Humm
  5. Larson
    Larson
  6. Scordo
    Scordo
  7. Cheung
    Cheung
  8. Fleisher
    Fleisher
  9. Hancock
    Hancock
  10. Lichtman
    Lichtman

Groups

  1. Department of Medicine (94)
  2. Solid Tumor Oncology Division (53)
  3. Sloan Kettering Institute Faculty (41)
  4. GSK Faculty (38)
  5. Molecular Pharmacology and Chemistry Program Faculty (37)
  6. Center for Hematologic Malignancies (36)
  7. Hematologic Malignancies, Division of (36)
  8. Pediatrics, Department of (30)
  9. Radiology, Department of (26)
  10. Tow Center for Developmental Oncology (TCDO) (25)
  1. "pharmacokinetics"
Formats
  1. Journal Article (239)
  2. Meeting Abstract (18)
  3. Review (13)
  4. Book Section (4)
  5. Conference Paper (3)
  6. Editorial (3)
  7. Book Whole (1)
  8. Correspondence (1)
  9. Research Letter (1)
Groups
  1. Department of Medicine (94)
  2. Solid Tumor Oncology Division (53)
  3. Sloan Kettering Institute Faculty (41)
  4. GSK Faculty (38)
  5. Molecular Pharmacology and Chemistry Program Faculty (37)
  6. Center for Hematologic Malignancies (36)

More Groups

People
  1. Gavril Pasternak (13)
  2. Charles Young (12)
  3. Steven Larson (12)
  4. Donna Niedzwiecki (10)
  5. John Humm (9)
  6. Ting-Chao Chou (9)

More People

Years
  1. 2025 (8)
  2. 2024 (25)
  3. 2023 (4)
  4. 2022 (5)
  5. 2021 (10)
  6. 2020 (11)

More Years

Publications
  1. Cancer Research (17)
  2. Proceedings of the American Association for Cancer Research Annual Meeting (13)
  3. Journal of Nuclear Medicine (10)
  4. Cancer (8)
  5. Cancer Chemotherapy and Pharmacology (7)
  6. Biochemical Pharmacology (5)

More Publications

Publishers
  1. Elsevier Inc. (45)
  2. American Association for Cancer Research (36)
  3. Springer (21)
  4. Wiley Blackwell (18)
  5. Oxford University Press (13)
  6. Lippincott Williams & Wilkins (11)

More Publishers

Results (283)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results: CHRONIC MYELOID LEUKEMIA
    Journal Article

    Hochhaus, A.; Kim, D. W.; Cortes, J. E.; Sasaki, K.; Mauro, M. J.; Hughes, T. P.; Breccia, M.; Talpaz, M.; Minami, H.; Goh, Y. T.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Phase 1 clinical trial of B-cell maturation antigen (BCMA) NEX-T® chimeric antigen receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
    Journal Article

    Ravi, G.; Richard, S.; Kumar, S.; Atrash, S.; Liedtke, M.; Kaur, G.; Derman, B.; Bergsagel, P. L.; Mailankody, S.; McCarthy, P.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Computational nuclear oncology toward precision radiopharmaceutical therapies: Current tools, techniques, and uncharted territories
    Review

    Yusufaly, T.; Roncali, E.; Brosch-Lenz, J.; Uribe, C.; Jha, A. K.; Currie, G.; Dutta, J.; El-Fakhri, G.; McMeekin, H.; Pandit-Taskar, N.; more...
    Journal of Nuclear Medicine (2025)

    Fulltext@MSK | Save
  • Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies
    Journal Article

    Lopez, J. S.; Milhem, M.; Butler, M. O.; Thistlethwaite, F.; Van Tine, B. A.; D'Angelo, S. P.; Johnson, M. L.; Sato, T.; Arkenau, H. T.; Edukulla, R.; more...
    Cell Reports Medicine (2025)

    Fulltext@MSK | Save
  • Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies
    Review

    Reinhorn, D.; Moskovitz, M.; Tap, W. D.; Li, B. T.
    Cancer (2025)

    Fulltext@MSK | Save
  • REZILIENT3: Randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC
    Journal Article

    Heymach, J. V.; Yu, H. A.; Besse, B.; Cheng, Y.; Tan, D. S. W.; Wei, L.; Wacheck, V.; Nishio, M.
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Strategies of positron emission tomography (PET) tracer development for imaging of tau and α-synuclein in neurodegenerative disorders
    Review

    Mekala, S.; Wu, Y.; Li, Y. M.
    RSC Medicinal Chemistry (2025)

    Fulltext@MSK | Save
  • Assessment of hypoxia in breast cancer: Emerging functional MR imaging and spectroscopy techniques and clinical applications
    Review

    Daimiel Naranjo, I.; Bhowmik, A.; Basukala, D.; Lo Gullo, R.; Mazaheri, Y.; Kapetas, P.; Eskreis-Winkler, S.; Pinker, K.; Thakur, S. B.
    Journal of Magnetic Resonance Imaging (2025)

    Fulltext@MSK | Save
  • Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): A multicentre, open-label, single-arm, phase 2 study
    Journal Article

    Zinzani, P. L.; Izutsu, K.; Mehta-Shah, N.; Barta, S. K.; Ishitsuka, K.; Córdoba, R.; Kusumoto, S.; Bachy, E.; Cwynarski, K.; Gritti, G.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors
    Journal Article

    Lenz, H. J.; Argilés, G.; de Jonge, M. J. A.; Yaeger, R.; Doi, T.; El-Khoueiry, A.; Eskens, F.; Kuboki, Y.; Bertulis, J.; Nazabadioko, S.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save